Baxter International Faces Class Action Lawsuit
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a highly regarded law firm, has informed investors that a class action lawsuit has been initiated against Baxter International, Inc. (NYSE: BAX) regarding serious allegations related to the company’s medical devices.
Understanding the Class Definition
This lawsuit aims to seek redress for damages caused by alleged violations of federal securities laws. It represents all individuals and entities that purchased Baxter securities during a specified Class Period, which spans from February 23, 2023, to July 30, 2025. Those affected are encouraged to join this action for potential relief.
Details of the Allegations
The core complaint suggests that Baxter misled its investors by failing to disclose critical information. Allegations include the company’s Novum LVP medical device suffering from systematic defects, leading to issues such as underinfusion and overinfusion, which posed critical risks to patient safety. Moreover, it has been indicated that Baxter was aware of multiple incidents involving device malfunctions, injuries, and even fatalities associated with these defects, yet failed to take adequate corrective action.
Impacts on Business Operations
Due to the persistent design flaws, the lawsuit suggests that numerous customers were forced to remove existing Novum LVPs from service, compounded by a complete halt on new sales of these pumps. Baxter’s previous statements regarding the safety and effectiveness of their devices are alleged to have been materially false and misleading.
The Next Steps for Investors
A class action lawsuit is officially underway. Interested parties can review the Complaint by accessing the law firm's resources. Contacting Bronstein, Gewirtz & Grossman, LLC could facilitate participation in this potentially significant legal process. Individuals impacted by the situation have a deadline to request lead plaintiff status, culminating on December 15, 2025.
No Financial Burden for Participants
Participants in this class action can benefit from a contingency arrangement, meaning the law firm will cover expenses and only seek reimbursement if there is a successful settlement.
Why Choose Bronstein, Gewirtz & Grossman?
This firm has a proven track record, having recovered substantial sums for investors in previous securities fraud cases. Their commitment to defending the rights of shareholders is well-documented, making them a compelling choice for individuals looking for legal representation in such matters.
Stay Updated with the Latest News
Investors are encouraged to follow the firm’s updates across major social media platforms to remain informed about the status of this case and other significant financial developments.
Contact Information
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
Frequently Asked Questions
What should I do if I invested in Baxter International?
If you invested during the Class Period, consider joining the class action lawsuit to seek potential damages.
Is there a cost involved in joining the lawsuit?
No, the firm works on a contingency fee basis, meaning you only pay if the lawsuit is successful.
What are the main allegations against Baxter International?
The allegations focus on misleading investors regarding the safety and performance of their Novum LVP medical devices.
How can I stay updated on the case?
Follow Bronstein, Gewirtz & Grossman, LLC on social media for the latest updates on the lawsuit.
When is the deadline to act?
The deadline to request lead plaintiff status is December 15, 2025.
